Gwo Xi Stem Cell Applied Technology Co. , Ltd
6704
Rank in Stocks
#21597
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem... Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
Share Price
$0.61578607
Last synced: 2026-11-10
Market Cap
$65.24M
Change (1 day)
0.25%
Change (1 year)
-27.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)
Category
Healthcare
Operating Margin for Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)
Operating Margin as of November 2026 TTM: -58.37%
According to Gwo Xi Stem Cell Applied Technology Co. , Ltd's latest financial reports, its current operating margin (TTM) is -58.37%. At the end of 2025 the company had an operating margin of -39.39%.
Operating Margin history for Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -58.37% | 48.18% |
| 2025 | -39.39% | -11.80% |
| 2024 | -44.66% | -32.89% |
| 2023 | -66.55% | 4.29% |
| 2022 | -63.81% | 55.79% |
| 2021 | -40.96% | 3.80% |
| 2020 | -39.46% | -16.24% |
| 2019 | -47.11% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.66% |
US
|
|
| -149.01% | -97.45% |
US
|
|
| 25.57% | -100.44% |
AU
|
|
| 31.23% | -100.54% |
BE
|
|
| 29.35% | -100.50% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin?
Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin is -58.37%, as of Nov 2026.
What was Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin in 2025?
In 2025, Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin was -39.39%, compared with -44.66% in 2024.
How has Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin changed since 2020?
From 2020 to 2025, Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin was highest in 2025 (-39.39%) and lowest in 2023 (-66.55%).
How does Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin compare with similar companies?
Gwo Xi Stem Cell Applied Technology Co. , Ltd's operating margin (-58.37%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.